Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 4/20 | 0.33 |
| ▸ | MMP13 | P45452 | 4/20 | 0.33 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722474 | 0.89 | DGAT1 (0.33) | EGLN1ALDH1A1MRGPRX4 | |
| SCHEMBL10208280 | 0.88 | TACR3 (0.32) | GPR84TACR3CASP3ALDH1A1KDM4E | |
| SCHEMBL721569 | 0.83 | CASP3 (0.43) | EGLN1CASP3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10208284 | 0.78 | MEN1 (0.34) | — | |
| SCHEMBL720280 | 0.76 | GPR84 (0.42) | GPR84CASP3ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31355239 | 0.74 | MMP9 (0.45) | EGLN1MBTPS1 | |
| SCHEMBL722494 | 0.73 | EGLN1 (0.39) | EGLN1MMP12MMP13CASP3ALDH1A1 | |
| SCHEMBL10208250 | 0.73 | CASP3 (0.40) | CASP3ALDH1A1KDM4EHSD17B10TP53 | |
| SCHEMBL721386 | 0.73 | TACR3 (0.42) | TACR3CASP3ALDH1A1HSD17B10TP53 | |
| SCHEMBL721679 | 0.73 | TACR3 (0.42) | TACR3CASP3ALDH1A1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | EGLN1 3778/4885GPR84 1977/4885TACR3 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.